Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas. One explanation for this effect is that hypermutated lesions harbor more tumor-specific neoantigens that stimulate recrui...

Descripción completa

Detalles Bibliográficos
Autores principales: Strickland, Kyle C., Howitt, Brooke E., Shukla, Sachet A., Rodig, Scott, Ritterhouse, Lauren L., Liu, Joyce F., Garber, Judy E., Chowdhury, Dipanjan, Wu, Catherine J., D'Andrea, Alan D., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924663/
https://www.ncbi.nlm.nih.gov/pubmed/26871470
http://dx.doi.org/10.18632/oncotarget.7277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924663/
https://www.ncbi.nlm.nih.gov/pubmed/26871470
http://dx.doi.org/10.18632/oncotarget.7277

Ejemplares similares